African-made antiretroviral generics are transforming HIV treatment access, with the first WHO-prequalified TLD regimen produced in Kenya and delivered to Mozambique in 2025. Local manufacturing is reducing dependence on imports, cutting costs, and building health sovereignty across the continent.